Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/10559
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12125]
Metadata
Show full item record
HIV AND HCV COINFECTION PREVALENCE, ASSOCIATED FACTORS AND GENOTYPE CHARACTERIZATION IN THE MIDWEST REGION OF BRAZIL
Author
Freitas, Solange Zacalusni
Teles, Sheila Araújo
Lorenzo, Paulo Cesar
Puga, Marco Antonio Moreira
Tanaka, Tayana Serpa Ortiz
Thomaz, Danilo Yamamoto
Martins, Regina Maria Bringel
Druzian, Angelita Fernandes
Lindenberg, Andréa Siqueira Campos
Torres, Marina Sawada
Pereira, Sérgio A
Villar, Livia Melo
Lampe, Elisabete
Castro, Ana Rita Coimbra Motta
Teles, Sheila Araújo
Lorenzo, Paulo Cesar
Puga, Marco Antonio Moreira
Tanaka, Tayana Serpa Ortiz
Thomaz, Danilo Yamamoto
Martins, Regina Maria Bringel
Druzian, Angelita Fernandes
Lindenberg, Andréa Siqueira Campos
Torres, Marina Sawada
Pereira, Sérgio A
Villar, Livia Melo
Lampe, Elisabete
Castro, Ana Rita Coimbra Motta
Affilliation
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Goiás. Goiânia, GO, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Goiás. Goiânia, GO, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Centro de Hematologia e Hemoterapia de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatite Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatite Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatite Viral. Rio de Janeiro, RJ, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil / Fundação Oswaldo Cruz. Campo Grande, MS, Brasil.
Universidade Federal de Goiás. Goiânia, GO, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Goiás. Goiânia, GO, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Centro de Hematologia e Hemoterapia de Mato Grosso do Sul. Campo Grande, MS, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatite Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatite Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatite Viral. Rio de Janeiro, RJ, Brasil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil / Fundação Oswaldo Cruz. Campo Grande, MS, Brasil.
Abstract
A cross-sectional study on prevalence, associated factors and genotype distribution of HCV infection was conducted among 848 HIV-infected patients recruited at reference centers in the Midwest Region of Brazil. The prevalence rate of HIV-HCV coinfection was 6.9% (95% CI: 5.2 to 8.6). In multivariable analysis, increasing age, use of illicit drugs (injection and non-injection), a history of blood transfusion before 1994, and the absence of a steady partnership were significant independent associated factors for HIV-HCV coinfection. The phylogenetic analysis based on the NS5B region revealed the presence of two major circulating genotypes of HCV: genotypes 1 (58.3%) and 3 (41.7%). The prevalence of HIV-HCV coinfection was lower than those reported in studies conducted with HIV-infected patients in different regions of Brazil, due to the fact that illicit drug use is not a frequent mode of HIV transmission in this region of Brazil. Serologic screening of HIV-patients for HCV before initiating antiretroviral treatment, a comprehensive identification of associated factors, and the implementation of effective harm reduction programs are highly recommended to provide useful information for treatment and to prevent HCV coinfection in these patients.
Share